Alerts will be sent to your verified email
Verify EmailMARKSANS
Marksans Pharma
|
Sanofi India
|
Ajanta Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
25.0 . | n/a | 76.0 . |
Number of ANDA's Approved By USFDA
|
13.0 . | n/a | 54.0 . |
R&D as a % of Total Sales
|
1.8 % | 0.0 | 5.0 % |
Financials
|
|||
5 yr Average ROE
|
17.94 % | 43.25 % | 19.25 % |
5yr average Equity Multiplier
|
1.39 | 3.33 | 1.34 |
5yr Average Asset Turnover Ratio
|
1.07 | 0.57 | 0.75 |
5yr Avg Net Profit Margin
|
12.37 % | 22.99 % | 19.31 % |
Price to Book
|
4.05 | 19.69 | 7.88 |
P/E
|
23.93 | 33.16 | 38.22 |
5yr Avg Cash Conversion Cycle
|
68.67 Days | 11.11 Days | 19.66 Days |
Inventory Days
|
88.63 Days | 48.47 Days | 74.91 Days |
Days Receivable
|
72.63 Days | 13.83 Days | 99.85 Days |
Days Payable
|
80.34 Days | 55.71 Days | 219.9 Days |
5yr Average Interest Coverage Ratio
|
27.58 | 1007.93 | 165.94 |
5yr Avg ROCE
|
23.34 % | 29.56 % | 24.04 % |
5yr Avg Operating Profit Margin
|
19.5 % | 28.62 % | 29.77 % |
5 yr average Debt to Equity
|
0.06 | 0.0 | 0.01 |
5yr CAGR Net Profit
|
28.35 % | 41.96 % | 8.73 % |
5yr Average Return on Assets
|
12.96 % | 13.01 % | 14.36 % |
Shareholdings
|
|||
Promoter Holding
|
43.85 % | 60.4 % | 66.21 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 12.26 % |
Change in Promoter Holding (3 Yrs)
|
-4.4 % | 0.0 | -4.13 % |
Change in Mutual Fund Holding (3 Yrs)
|
4.14 % | 1.86 % | 5.23 % |
Marksans Pharma
|
Sanofi India
|
Ajanta Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Customer Segment
|
Customer Segment
|
-
|
-
|